News

InDevR Cypher One™ Collaborative Study With FDA Published

Tuesday, July 18, 2017

BOULDER, Colo.--(BUSINESS WIRE)--InDevR, Inc., an innovative life science company dedicated to improving biopharmaceutical and vaccine manufacturing, announced study results and a joint publication with the U.S. Food and Drug Administration (FDA) of “Automated interpretation of influenza hemagglutination inhibition (HAI) assays: is plate tilting necessary?” in the scientific journal PLOS ONE

AntriaBio closes $13M private placement

Monday, July 17, 2017

LOUISVILLE — AntriaBio Inc. (OTC: ANTB) closed a $13 million private placement transaction and plans to dose its first patient this month.

The biopharmaceutical company specializes in drug therapies for patients with diabetes and metabolic diseases.

Full Story via BizWest

 
Continue Reading

Tapped by WHO - PharmaJet Raises $3M

Tuesday, July 11, 2017

With polio vaccine in short supply, the World Health Organization has tapped a Golden-based medical device startup to help fill the gap. 

Lung Cancer: VeriStrat® Test Identifies Patients with Squamous Cell Carcinoma of the Lung Who Are More Likely to Have Improved Survival on Afatinib Therapy

Monday, July 10, 2017

Biodesix’ blood-based VeriStrat test helps identify squamous NSCLC patients for afatinib therapy 

HemoGenix Licenses Assays and Reagents to Preferred Cell Systems

Thursday, July 06, 2017

Colorado Springs, CO – HemoGenix, Inc. is pleased to announce that it has licensed the manufacturing, sales and marketing of its proprietary reagents and in vitro assay kits to Preferred Cell Systems. 

Array Biopharma Files New Drug Applications and Stock Price Climbs

Wednesday, July 05, 2017

BOULDER — Cancer-research firm Array Biopharma Inc. (Nasdaq: ARRY) filed new-drug applications with the U.S. Food and Drug Administration.

The drug applications are for the combined use of 45 milligrams of binimetinib twice a day with 450 milligrams of encroafenib once a day for the treatment of patients with advanced or metastatic melanoma.

Full Story via BizWest

 
Continue Reading

AmideBio Is Granted European Patent for its Foundational Peptide Production Platform Technology

Saturday, July 01, 2017

BOULDER, CO, July 01, 2017 – AmideBio, LLC, a privately held biopharmaceutical company, announced today that the European patent office had granted European Patent 2787083 “Efficient Production of Peptides”. The patent expands the Company’s patent portfolio for its core platform technology, BioPure™ which enables the cost-efficient production of high purity peptides, including peptides that are hard to produce by standard methods. The equivalent US patent (8,796,431) was granted in 2014. The BioPure process facilitates rapid structure activity relationship (rSAR) studies on high value peptide therapeutics and lowers the downstream production costs for difficult to manufacture peptides. The Company is leveraging the technology to produce its own pipeline of therapeutics while providing custom specified peptides to companies looking to obtain high purity products for research. 

Angel® Catheter Pivotal Study Published in Journal of Vascular and Interventional Radiology

Thursday, June 29, 2017

GOLDEN, Colo., June 29, 2017 /PRNewswire/ -- Bio2 Medical today announced the results of the Angel® Catheter pivotal study, "Evaluation of a Device Combining an Inferior Vena Cava Filter and a Central Venous Catheter for Preventing Pulmonary Embolism Among Critically Ill Trauma Patients," published in the Journal of Vascular and Interventional Radiology (JVIR). The Angel® Catheter met all safety endpoints and demonstrated a significant reduction in clinically significant and fatal pulmonary embolism (PE). The novel device was tested in a single arm, multicenter clinical trial in which it was inserted bedside in the intensive care unit (ICU) without fluoroscopy, and safely retrieved from all patients prior to discharge. The study included 163 critically ill patients with high risk of acute PE and contraindications to anticoagulation, with 151 (93%) critical trauma patients. In this trauma group, 129 (85%) patients suffered from spinal or head trauma, 102 (79%) of which also had intracranial bleeding. With no catheter-related blood stream infections (CRBSI), the Angel® Catheter successfully averted PEs in 14 (11%) of the 129 patients with a pre-removal cavogram. The data will be presented at the 76th Annual Meeting of AAST and Clinical Congress of Acute Care Surgery. 

AmideBio to present a novel treatment for hyperinsulinism at the International Congenital Hyperinsulinism Conference July 15-16, 2017 at the Stockton Seaview Hotel, Galloway, New Jersey

Monday, June 26, 2017

BOULDER, CO, June 26, 2017 – AmideBio, LLC, a privately-held biopharmaceutical company, today announced that AmideBio’s Chief Technology Officer, Dr. Michael H. B. Stowell will present a talk titled “Novel Pumpable Glucagons for Treatment of Hyperinsulinism” at the 2017 International Congenital Hyperinsulinism Conference July 15-16, 2017, hosted by the Children’s Hospital of Philadlephia (CHOPS) and Congenital Hyperinsulinism International (CHI), a charitable organization dedicated to improving the lives of children, adults, and families living with congenital hyperinsulism. 

ARCA Biopharma Announces Database Lock for GENETIC-AF Phase 2B Interim Efficacy Analysis – DSMB Recommendation Anticipated in August 2017

Tuesday, June 20, 2017

WESTMINSTER, Colo., June 20, 2017 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced database lock for the GENETIC-AF Phase 2B interim efficacy analysis, to be conducted by the trial Data Safety Monitoring Board (DSMB). GENETIC-AF is a seamless design Phase 2B/3 clinical trial evaluating GencaroTM (bucindolol hydrochloride) as a potential treatment for atrial fibrillation (AF). The Company expects to announce the DSMB’s recommendation based on this interim analysis in August 2017. The Gencaro development program has previously been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).